(Q37235537)

19 August 2017

1 reference

title

Obstacles to successful HCV treatment in substance addicted patients (English)

1 reference

19 August 2017

0 references

Curtis L Cooper

1

1 reference

19 August 2017

1 January 2008

1 reference

Journal of Addictive Diseases

19 August 2017

1 reference

19 August 2017

27

1 reference

19 August 2017

2

1 reference

19 August 2017

61-68

1 reference

Hepatitis C virus: epidemiology and transmission

19 August 2017

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Nonadherence in tuberculosis treatment: predictors and consequences in New York City.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Compliance with treatment regimens in chronic asymptomatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

High Compliance with a Hepatitis B Virus Vaccination Program among Intravenous Drug Users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Treatment of hepatitis C infection in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Cannabis use improves retention and virological outcomes in patients treated for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Alcohol and HIV risk taking among intravenous drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Therapeutic challenges in hepatitis C-infected injection drug using patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Hepatitis C and alcohol: interactions, outcomes, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Alcohol use and treatment of hepatitis C virus: results of a national multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Marijuana smoking and head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Cigarette smoking and hepatic lesions in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Hepatitis C virus infection: impacts on behaviour and lifestyle

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Interest in smoking cessation among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Smoking and alanine aminotransferase levels in hepatitis C virus infection: implications for prevention of hepatitis C virus progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Impact of smoking on histological liver lesions in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Smoking and smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Nutritional assessment in intravenous drug users with HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Different degrees of malnutrition and immunological alterations according to the aetiology of cirrhosis: a prospective and sequential study

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Drug abuse and psychiatric comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Depression, fatigue, and functional disability in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Treating hepatitis C in methadone maintenance patients: an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Crack across Canada: Comparing crack users and crack non-users in a Canadian multi-city cohort of illicit opioid users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Medical care for injection-drug users with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Adherence to treatment in Swedish HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

Prevention and treatment of hepatitis C in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_07

21 January 2018

Identifiers

DOI

10.1300/J069V27N02_07

1 reference

19 August 2017

1 reference

PubMed ID

18681192